Navigation Links
Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
Date:7/7/2008

BELLEVUE, Wash., July 7 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment under development. LSO plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the United States as well as a 40-patient, Phase IIa study in Australia, expected to begin during the current quarter.

"Treating patients with this serious quality-of-life problem is an important milestone for our Litx technology," said Llew Keltner, M.D., Ph.D., President and Chief Executive Officer of LSO. "We plan to continue to demonstrate the broader applicability of Litx beyond oncology." LSO currently is conducting Phase III clinical studies of Litx in patients with hepatoma (primary liver cancer) and metastatic colorectal cancer and expects to initiate a Phase III clinical study in glioma in the second half of 2008.

BPH is a common result of aging and is estimated to occur in more than 14 million American men. BPH rarely causes symptoms before age 40, but more than half of men in their sixties and as many as 90 percent in their seventies and eighties have some symptoms of BPH, which typically include painful and frequent urination caused by the enlarged prostate's reduction of urine flow through the urethra. Early stage treatment is critical, because severe BPH can cause serious problems over time, such as urinary tract infections, bladder stones, incontinence, and eventually untreatable bladder or kidney damage.

Litx uses light-emitting diodes (LEDs) to activate LS11 (talaporfin sodium) molecules. Once activated, these molecules cause the production of singlet oxygen, which can kill target tissues with minimal side effects through vascular closure and apoptosis, or "programmed cell death." The single-use, disposable Litx device contains a tiny array of LEDs.

In the Litx BPH application, a modified standard urethral catheter positions the proprietary light-emitting LED array precisely within the prostate. After systemic injection of LS11, the LEDs are turned on, and activation of the drug occurs locally within the prostate. When the short treatment is complete, the LED-containing catheter is removed and thrown away. The goal of the therapy is to kill prostate tissue via apoptosis within a highly localized zone in the prostate, without causing inflammation. The short, single outpatient treatment is designed to effectively re-establish and maintain an unobstructed urine flow, relieving BPH symptoms.

ABOUT LIGHT SCIENCES ONCOLOGY

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)) to provide safer and more effective treatment for cancer and other conditions. In addition to the Phase III trials in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the Company has completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened the scope of potential therapeutic applications of the versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease and dermatology. The Company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.

Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light Sciences Oncology, Inc.

Contact:

Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer

425-957-8900

bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.

President and CEO

425-957-8900

dr_llew@lsoncology.com

website: http://www.lsoncology.com


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
2. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
3. New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
4. Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
5. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
6. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
9. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
10. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
(Date:1/20/2017)... Fla. , Jan. 20, 2017 Wells Specialty ... at 3796 Howell Branch Rd in Winter Park, ... Winter Park . Operations have been consolidated into ... Pharmacy is also pleased to announce that Chad Tomlinson ... President of the Company effective immediately. Mr. Tomlinson is a ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica ... Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home 2017,” ... community. “Coming Home 2017” will be held on Friday January 27 through ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million women ... of recovery, they often feel shame for having struggled with an eating disorder as ... the workshop, “Rising Strong in Life After an Eating Disorder” -- to be featured ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... A new ... donate items they no longer use or need, from clothes to couches to dressers ... unwanted items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... ... ... Doctor C LLC, a company based out of Arizona that focuses on ... marketing and distribution of its product, The Right C. , The Right C is ... traditional vitamin C supplements. At the trade show, Doctor C had the opportunity to ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an ... lives, recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting ... its large range of supplements that keep the body functioning at its peak ...
Breaking Medicine News(10 mins):